Have your own idea? Try our Stock Screener
Taiwanese (TAIEX) Biotech Industry Analysis
UpdatedMar 05, 2026
DataAggregated Company Financials
Companies70
- 7D-6.8%
- 3M11.0%
- 1Y5.6%
- YTD12.7%
Over the last 7 days, the Biotech industry has dropped 6.8%, driven by a pullback from PharmaEssentia of 4.1%. On the other hand TCM Biotech International is actually up 23%. This takes the industry's 12 month performance to a gain of 5.6%. Looking forward, earnings are forecast to grow by 38% annually.
Industry Valuation and Performance
Has the Taiwanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 06 Mar 2026 | NT$656.0b | NT$35.2b | -NT$8,700,432,500.00 | 29.6x | -75.4x | 18.6x |
| Sun, 01 Feb 2026 | NT$701.2b | NT$33.4b | -NT$8,524,146,000.00 | 29.4x | -82.3x | 21x |
| Tue, 30 Dec 2025 | NT$565.3b | NT$33.4b | -NT$6,808,544,000.00 | 30.3x | -83x | 16.9x |
| Thu, 27 Nov 2025 | NT$551.8b | NT$33.0b | -NT$7,467,266,000.00 | 38.8x | -73.9x | 16.7x |
| Sat, 25 Oct 2025 | NT$554.8b | NT$32.2b | -NT$8,364,979,000.00 | 35.1x | -66.3x | 17.2x |
| Mon, 22 Sep 2025 | NT$549.2b | NT$32.2b | -NT$8,364,979,000.00 | 35.2x | -65.7x | 17x |
| Wed, 20 Aug 2025 | NT$515.1b | NT$32.3b | -NT$8,056,711,000.00 | 40.8x | -63.9x | 16x |
| Fri, 18 Jul 2025 | NT$512.3b | NT$30.2b | -NT$6,412,141,000.00 | 36.9x | -79.9x | 17x |
| Sun, 15 Jun 2025 | NT$507.0b | NT$30.2b | -NT$6,460,452,000.00 | 37.7x | -78.5x | 16.8x |
| Tue, 13 May 2025 | NT$490.1b | NT$30.3b | -NT$6,456,063,000.00 | 36x | -75.9x | 16.2x |
| Thu, 10 Apr 2025 | NT$400.9b | NT$28.1b | -NT$7,302,014,000.00 | 26x | -54.9x | 14.3x |
| Sat, 08 Mar 2025 | NT$538.3b | NT$28.0b | -NT$8,407,141,000.00 | 33.6x | -64x | 19.3x |
| Mon, 03 Feb 2025 | NT$550.6b | NT$24.8b | -NT$10,902,841,000.00 | 34.9x | -50.5x | 22.2x |
| Wed, 01 Jan 2025 | NT$515.8b | NT$24.8b | -NT$10,902,841,000.00 | 34x | -47.3x | 20.8x |
| Fri, 29 Nov 2024 | NT$500.2b | NT$24.8b | -NT$10,782,551,000.00 | 36.7x | -46.4x | 20.2x |
| Sun, 27 Oct 2024 | NT$545.2b | NT$23.5b | -NT$10,829,095,000.00 | 39x | -50.3x | 23.2x |
| Tue, 24 Sep 2024 | NT$579.7b | NT$23.5b | -NT$10,829,095,000.00 | 35x | -53.5x | 24.7x |
| Thu, 22 Aug 2024 | NT$571.0b | NT$23.6b | -NT$10,755,142,000.00 | 34.7x | -53.1x | 24.2x |
| Sat, 20 Jul 2024 | NT$572.5b | NT$21.9b | -NT$11,110,643,000.00 | 42.4x | -51.5x | 26.1x |
| Mon, 17 Jun 2024 | NT$513.1b | NT$21.9b | -NT$11,110,643,000.00 | 42.7x | -46.2x | 23.4x |
| Wed, 15 May 2024 | NT$465.2b | NT$21.0b | -NT$12,438,653,000.00 | 34.5x | -37.4x | 22.2x |
| Fri, 12 Apr 2024 | NT$458.9b | NT$21.1b | -NT$11,599,476,000.00 | 51.2x | -39.6x | 21.8x |
| Sun, 10 Mar 2024 | NT$436.2b | NT$20.8b | -NT$9,880,735,000.00 | 38.8x | -44.1x | 21x |
| Tue, 06 Feb 2024 | NT$436.3b | NT$19.9b | -NT$9,830,596,000.00 | 40.5x | -44.4x | 21.9x |
| Thu, 04 Jan 2024 | NT$465.9b | NT$19.8b | -NT$9,748,146,000.00 | 39.4x | -47.8x | 23.6x |
| Sat, 02 Dec 2023 | NT$486.1b | NT$19.9b | -NT$9,737,975,000.00 | 42.8x | -49.9x | 24.5x |
| Mon, 30 Oct 2023 | NT$472.4b | NT$18.4b | -NT$10,823,013,000.00 | 51.5x | -43.6x | 25.6x |
| Wed, 27 Sep 2023 | NT$474.7b | NT$18.3b | -NT$10,774,227,000.00 | 42.6x | -44.1x | 25.9x |
| Fri, 25 Aug 2023 | NT$477.9b | NT$18.2b | -NT$10,711,380,000.00 | 41.9x | -44.6x | 26.2x |
| Sun, 23 Jul 2023 | NT$481.3b | NT$18.7b | -NT$10,724,655,000.00 | 46x | -44.9x | 25.8x |
| Tue, 20 Jun 2023 | NT$480.0b | NT$18.7b | -NT$10,709,428,000.00 | 42.9x | -44.8x | 25.7x |
| Thu, 18 May 2023 | NT$487.8b | NT$19.3b | -NT$9,957,876,000.00 | 43.1x | -49x | 25.3x |
| Sat, 15 Apr 2023 | NT$512.9b | NT$18.5b | -NT$9,600,625,000.00 | 42.9x | -53.4x | 27.7x |
| Mon, 13 Mar 2023 | NT$510.5b | NT$22.3b | -NT$7,221,244,000.00 | 37.4x | -70.7x | 22.9x |
Price to Earnings Ratio
-70.7x
Current Industry PE
- Investors are pessimistic on the Taiwanese Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 21.7x is higher than the industry's current PS ratio of 18.6x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 16% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Taiwanese Healthcare industry?
| TW Market | -7.21% | |
| Healthcare | -7.09% | |
| Biotech | -6.82% | |
| Biotech | -6.82% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 4169 TCM Biotech International | NT$240.50 | 22.7% +NT$2.6b | 312.5% | PE673.7x | |
| 7827 HanchorBio | NT$163.50 | 7.6% +NT$1.5b | n/a | PS68.1x | |
| 4147 TaiMed Biologics | NT$54.30 | 5.6% +NT$792.3m | -42.4% | PS24.4x | |
| 6492 Senhwa Biosciences | NT$52.50 | 4.6% +NT$205.1m | 18.5% | PS4335.4x | |
| 1780 Allied Biotech | NT$25.90 | 3.6% +NT$86.6m | 42.7% | PE26.4x |